

Pearls

Igniting the Fire: *Staphylococcus aureus* Virulence Factors in the Pathogenesis of Sepsis

Michael E. Powers¹, Juliane Bubeck Wardenburg^{1,2*}

1 Department of Microbiology, The University of Chicago, Chicago, Illinois, United States of America, **2** Department of Pediatrics, The University of Chicago, Chicago, Illinois, United States of America

Sepsis is a devastating disease process characterized by a systemic inflammatory response in the host, evoked by a known or suspected pathogen. *Staphylococcus aureus* has emerged as a leading etiologic agent of sepsis, owing to its propensity to cause deep-seated tissue infection and bacteremia [1]. *S. aureus* harbors an arsenal of virulence factors to facilitate tissue adhesion, immune evasion, and host cell injury. In the bloodstream, these factors cause inflammation, impair immune cell function, alter coagulation, and compromise vascular integrity. This review will discuss key secreted and surface-anchored proteins required for *S. aureus* infection in the hostile host environment of the bloodstream, emphasizing mechanistic insights on virulence factor function that illustrate the complex nature of the host–pathogen interaction. While we currently lack a clear understanding of the temporal and spatial integration of these virulence factors in the bloodstream, it is apparent that *S. aureus* triggers pathophysiologic disturbances that are further amplified by the host inflammatory response, culminating in the severe clinical manifestations of sepsis and septic shock.

Inflammation: An Early *S. aureus* Insult in Sepsis

The clinical manifestations of sepsis span a continuum of severity, in the most extreme form termed “septic shock,” in which vascular insults and systemic inflammation lead to compromised cardiac function and blood pressure, culminating in impaired oxygen delivery to the tissues and organ failure. In the United States, ~750,000 individuals suffer from sepsis per year, with mortality rates that approach or even exceed 50% in severe disease [2]. Multiple clinical trials aimed at curbing the host inflammatory response to severe infection have yielded limited clinical success [3]. The mainstay of therapy for sepsis and septic shock remains 2-fold: (1) rapid treatment of the underlying infection and (2) early resuscitation to blunt physiologic abnormalities that potentiate disease progression [4]. The nature of these beneficial interventions focuses attention on rigorously defining the inciting insult caused by the pathogen.

Multiple *S. aureus* proteins and cell wall components are pro-inflammatory, eliciting host responses similar to gram-negative lipopolysaccharide (LPS) [5]. The production of cytokines, including TNF- α and IL-6, results from the action of *S. aureus* lipoproteins on mononuclear phagocytes through TLR-2 pathway activation [6,7]. Furthermore, bloodstream exposure of rat hosts to peptidoglycan and lipoteichoic acid leads to induction of IL-1 and IFN- γ [8]. Toxin-induced cellular injury also elicits prominent host inflammatory responses. In the bloodstream, circulating immune cells and the vascular endothelium are primary targets of staphylococcal virulence factors. Among the longest studied of these toxins are the staphylococcal superantigens that potently stimulate non-specific T-cell proliferation and activation and potentiate the host inflammatory response associated with sepsis [9]. A family of bi-component leukotoxins including Pantone-Valentine Leukocidin (PVL), Leukocidin AB/GH (LukAB/GH), Leukocidin ED (LukED), and γ -hemolysin (Hlg) injure an array of leukocytes including neutrophils, mononuclear phagocytes, and T

cells [10]. Also contributing to leukocyte injury is the family of cytolytic peptides termed phenol soluble modulins (PSMs) [11] and the small pore-forming toxin α -hemolysin (α -toxin, Hla) (Figure 1a) [12]. Genetic regulatory control that leads to increased production of PVL, PSMs, and α -toxin in highly virulent methicillin-resistant *S. aureus* (MRSA) strains has been described as a molecular mechanism that underlies increased disease severity observed upon infection with these isolates [13–15]. These virulence factors are potent stimulants of leukocyte inflammatory responses [10,12,16]. *S. aureus* mutants engineered to lack expression of even one of these toxins exhibit virulence defects in experimental infection [11,17–19], suggesting that the collective impact of this group of toxins on inflammation and destabilization of the host during bloodstream infection is substantial.

Escape from Innate Immune Cells: A Key to Bloodstream Survival

In concert with direct leukocyte injury, *S. aureus* utilizes a number of strategies to modulate the innate host immune response and prevent bacterial clearance in the bloodstream [20]. Most clinical *S. aureus* isolates express a polysaccharide capsule that affords protection against phagocyte-mediated clearance; furthermore, the pathogen is able to resist killing in the phagocyte. *S. aureus* also secretes factors that function to dampen leukocyte recruitment or prevent opsonophagocytic uptake as a predecessor to intracellular killing. Two of the best-studied of these proteins are Chemotaxis Inhibitory Protein of Staphylococci (CHIPS) and Staphylococcal Complement Inhibitor (SCIN). CHIPS binds to the cellular receptors for C5a and N-formyl peptides, diminishing the ability of both bacterial peptides and complement activation to function as leukocyte chemoattractants (Figure 1b) [21,22]. SCIN

Citation: Powers ME, Bubeck Wardenburg J (2014) Igniting the Fire: *Staphylococcus aureus* Virulence Factors in the Pathogenesis of Sepsis. PLoS Pathog 10(2): e1003871. doi:10.1371/journal.ppat.1003871

Editor: Joseph Heitman, Duke University Medical Center, United States of America

Published: February 13, 2014

Copyright: © 2014 Powers, Bubeck Wardenburg. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH award AI097434-01 to JBW. The authors also acknowledge membership in and support from the Region V “Great Lakes” RCE (NIH award 2-U54-AI-057153). MEP was partially supported by NIH Grant T32 GM007183 and American Heart Association pre-doctoral fellowship 13PRE14560065. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal’s policy and have the following conflicts: JBW has the potential to receive royalties from Novartis Vaccines and Diagnostics in relation to patents owned by the University of Chicago. This does not alter our adherence to all PLOS policies on sharing data and materials.

* E-mail: jbubeckw@peds.bsd.uchicago.edu




Figure 1. Overview of *S. aureus* virulence factors that contribute to the pathogenesis of sepsis. (a) Leukocytes are targeted and injured by bi-component leukocidins (PVL, LukAB/GH, LukED, and Hlg, blue and orange), phenol-soluble modulins (PSM, purple), and α -toxin (Hla, green). (b) Inhibition of host complement pathways occurs through Chemotaxis Inhibitory Protein of Staphylococci (CHIPS) binding to the C5a receptor and (c) Staphylococcal Complement Inhibitor (SCIN)-mediated blockade of C3 convertase activity. (d) Staphylococcal protein A (SpA) binds to host antibodies, preventing opsonophagocytosis and contributing to apoptotic death of B cells. (e) Coagulase (Coa) and von Willebrand factor binding protein (vWbp) initiate fibrin clot formation, facilitating the formation of staphylococcal aggregates in the blood through the action of clumping factors A and B (ClfA/B). (f) Platelet traps surround staphylococci that adhere to macrophage-like Kupffer cells in the liver sinusoid. (g) Fibronectin-binding proteins A and B (FnBPA/B) bind to integrin $\alpha 5 \beta 1$, enabling the tethering of *S. aureus* to endothelial cells in the context of blood flow. (h) Expression of *S. aureus* α -toxin (Hla) causes direct injury to the endothelium, disrupting the integrity of the endothelial barrier. doi:10.1371/journal.ppat.1003871.g001

potently inhibits human complement pathway defenses by blocking C3 convertase activity, reducing the deposition of the C3b opsonin on *S. aureus* and decreasing neutrophil uptake and killing [23] (Figure 1c). Both of these staphylococcal virulence factors display human specificity and are secreted during early bacterial growth to provide rapid evasion of innate immunity [24].

To limit the function of innate immune cells that successfully circumvent anti-chemotactic signals, *S. aureus* utilizes the cell-wall-anchored Staphylococcal protein A (SpA) to preclude antibody-driven opsonophagocytic clearance. SpA binds to the F_c and F_{ab} regions of host antibodies [25], preventing staphylococcal antigen recognition and F_c-mediated effector functions. SpA also engages the B cell receptor and initiates activation-induced apoptotic death of V_H3⁺ B cells (Figure 1d) [26]. *S. aureus* SpA mutants display virulence defects in an intraperitoneal model of lethal infection as well as intravenous infection that leads to arthritis and renal abscess formation [27–29]. Immunization with an inactive, “non-toxinogenic” SpA variant is protective in lethal *S. aureus* sepsis, promoting opsonophagocytic clearance in the blood [28]. In addition to these immunoevasion strategies and the broadly toxic effects of the array of staphylococcal toxins on host immune cells [10–12], recent studies indicate a prominent role for LukED in bloodstream infection by virtue of its ability to injure monocytes and lymphocytes, diminishing phagocytic uptake and promoting pathogen dissemination [18,30]. Collectively, these bacterial defense mechanisms increase the burden of staphylococci in the blood, further compromising the septic host.

Modulation of Intravascular Coagulation: A Host-Pathogen Tug-of-War

Coagulopathy is another hallmark of septic shock, manifest as pathologic clotting within the microvasculature and a

predisposition toward systemic bleeding [3]. *S. aureus* encodes virulence factors that modulate both soluble and cell-mediated pathways of coagulation. Physiologic coagulation in response to injury requires the rapid, localized activation of platelets, together with activation of the soluble clotting cascade. This serine protease-based cascade culminates in the enzymatic conversion of prothrombin to thrombin, in turn promoting the cleavage of fibrinogen to soluble fibrin monomers that polymerize into insoluble fibrin. Platelet-fibrin matrices form a physical substrate for plugging of the injured vasculature. While these processes are tightly regulated to ensure hemostasis yet avoid untoward intravascular thrombosis, bacterial virulence factors and the underlying host inflammatory state in sepsis induce pathologic alterations of coagulation. The staphylococcal virulence factors coagulase (Coa) and von Willebrand factor binding protein (vWbp) promote the non-catalytic activation of prothrombin, yielding cleavage of soluble fibrinogen to engender fibrin clot formation in the absence of an inciting injury [31,32]. Fibrin clots promote clumping factor protein-mediated (ClfA and ClfB) aggregation of staphylococci (Figure 1e) [27]. Agglutination of *S. aureus* in the blood promotes bacterial survival, noted by the significant virulence defect in *S. aureus* strains that lack expression of Coa, vWbp, and ClfA [33]. In this context, survival is favored by protection of the aggregated organisms against phagocytic clearance. As activation of host coagulation pathways is proinflammatory [34], manipulation of this pathway by *S. aureus* likely contributes to the systemic inflammatory response.

Recent observations indicate the importance of thrombosis in immunodefense [35], demonstrating that platelets confer anti-staphylococcal immunity to bloodstream infection [36]. Intravital imaging revealed that platelets form aggregates around staphylococci adhered to macrophage-like Kupffer cells associated with the liver sinusoidal endothelium, entrapping *S. aureus* and facilitating

pathogen clearance (Figure 1f) [36]. Suggesting the host-protective role of these traps, experimental platelet depletion leads to increased mortality from bloodstream infection [36]. While the role of platelets as innate immune cells has recently gained considerable attention, the modulation of normal platelet function by *S. aureus* has long been suggested by the ability of α -toxin to initiate platelet activation and aggregation [37]. α -toxin-induced platelet activation would thereby seem to promote the formation of platelet traps and support bacterial clearance—a paradoxical “anti-virulence” effect, highlighting the need to further investigate the precise molecular mechanisms by which staphylococcal virulence factors modulate platelet function in innate immunity.

The Microvascular Endothelium: A Site of Coordination?

Blood flow presents a major hurdle to both the pathogen and the host during intravascular infection. The ability of immune cells to identify and then contain *S. aureus* in the context of a branching vascular tree and the dilutional effects of blood flow is challenged. Conversely, the pathogen is challenged to (1) constrain the delivery of soluble virulence factors that initiate pathologic coagulation in flowing blood and (2) overcome fluid shear stress to adhere to the vascular wall and promote dissemination. Fibronectin-binding protein A (FnBPA) is a surface-displayed protein that facilitates endothelial adherence (Figure 1g) [38]. Variations in FnBPA underlie differences in fibronectin-binding affinity; high-affinity variants enhance endothelial cell binding and correlate with increased endothelial invasion in bloodstream infection [38]. The initial tethering of *S. aureus* to the endothelium may favor the establishment of a microenvironment in the small vessels or slow-flow vessels, such as liver sinusoids, in which *S. aureus*-induced coagulation and aggregate formation enhances the localized elaboration of virulence factors (Figure 1h) [39].

A primary molecular mechanism for bacterial-induced vascular permeability is endothelial disruption due to extreme inflammation [34]. In addition to its role in leukocyte and platelet injury, recent studies suggest that α -toxin co-opts the function of its cellular receptor ADisintegrin and Metalloprotease 10 (ADAM10) to disrupt the endothelial barrier by promoting the untimely cleavage of vascular endothelial (VE)-cadherin, destroying the inter-cellular junction that is required for vascular integrity [17]. As an intact endothelium forms the principal physical barrier to intravascular dissemination of bacterial pathogens, disruption of this barrier is expected to promote dissemination, a common and severe consequence of *S. aureus* sepsis. Damaged endothelium is

also a potent stimulus for the rapid recruitment of platelets and activation of soluble clotting cascades. The microvascular endothelial surface may, thus, form a site wherein the pathogen, its armamentarium of virulence factors, platelets, leukocytes, and host coagulation proteins are co-localized. This “coordination” site may simultaneously trigger microvascular occlusion and increased vascular permeability—events that decrease effective blood flow to the tissues and precipitate sepsis-associated vital organ failure.

Towards the Future: Insights That May Change *S. aureus* Sepsis

The devastating mortality of sepsis and the inability of current clinical approaches to mitigate disease testify to our limited understanding of the complex host–pathogen interaction in the bloodstream. While the virulence factors discussed herein each contributes to sepsis pathogenesis, loss of any one factor is insufficient for complete protection against experimental *S. aureus* challenge. Similarly, vaccine approaches that target isolated virulence factors do not provide complete protection against lethal sepsis [40]. Together, these observations highlight our need to understand the temporospatial regulation of virulence factor expression and action in vivo. While exaggerated host inflammatory responses are associated with the progression of severe septic shock, insults directly delivered by *S. aureus*—coagulopathy, immune cell injury, microvascular occlusion, and barrier damage—collectively mirror disease endpoints in sepsis. These insults likely initiate the very pathophysiological state that is then exacerbated by an untoward host response. While multiple blood-borne bacteria incite endothelial injury and lead to a coagulopathic state manifested as sepsis [41], whether a deliberate pathogen-driven coordination of these events occurs to promote virulence requires further study. The host–pathogen interaction in the bloodstream has proven extremely challenging to redirect in favor of the host, in spite of the commonality of these observed physiologic disturbances. The essential role of bacterial virulence factors as catalysts of sepsis, however, suggests that a keen focus on understanding how these factors are integrated in time and space within the vasculature should yield new insights for sepsis prevention and therapy in the coming years.

Acknowledgments

We thank Nathania Hau for compilation of the figure depicting *S. aureus* virulence factors in the bloodstream.

References

- Lowy FD (1998) *Staphylococcus aureus* infections. N Engl J Med 339: 520–532.
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310.
- Russell JA (2006) Management of sepsis. N Engl J Med 355: 1699–1713.
- Cannon CM, Holthaus CV, Zubrow MT, Posa P, Gunaga S, et al. (2012) The GENESIS Project (GENeralized Early Sepsis Intervention Strategies): A Multicenter Quality Improvement Collaborative. J Intensive Care Med 28: 355–368.
- Salomao R, Brunialti MK, Rapozo MM, Baggio-Zappia GL, Galanos C, et al. (2012) Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 38: 227–242.
- Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, et al. (2006) Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in *Staphylococcus aureus*. J Immunol 177: 3162–3169.
- Bubeck Wardenburg J, Williams WA, Missiakas D (2006) Host defenses against *Staphylococcus aureus* infection require recognition of bacterial lipoproteins. Proc Natl Acad Sci U S A 103: 13831–13836.
- De Kimpse SJ, Kengatharan M, Thiemeermann C, Vane JR (1995) The cell wall components peptidoglycan and lipoteichoic acid from *Staphylococcus aureus* act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A 92: 10359–10363.
- Salgado-Pabon W, Breshears L, Spaulding AR, Merriman JA, Stach CS, et al. (2013) Superantigens are critical for *Staphylococcus aureus* Infective endocarditis, sepsis, and acute kidney injury. MBio 4: e00494-13.
- Yoong P, Torres VJ (2013) The effects of *Staphylococcus aureus* leukotoxins on the host: cell lysis and beyond. Curr Opin Microbiol 16: 63–69.
- Wang R, Braughton KR, Kretschmer D, Bach T-HL, Queck SY, et al. (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nature Medicine 13: 1510–1514.
- Berube BJ, Bubeck Wardenburg J (2013) *Staphylococcus aureus* alpha-Toxin: Nearly a Century of Intrigue. Toxins (Basel) 5: 1140–1166.
- Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, et al. (2009) Evolution of virulence in epidemic community-associated methicillin-resistant *Staphylococcus aureus*. Proc Natl Acad Sci U S A 106: 5883–5888.
- Chua KY, Seemann T, Harrison PF, Monagle S, Korman TM, et al. (2011) The dominant Australian community-acquired methicillin-resistant *Staphylococcus aureus* clone ST93-IV [2B] is highly virulent and genetically distinct. PLoS One 6: e25887. doi:10.1371/journal.pone.0025887

15. DeLeo FR, Kennedy AD, Chen L, Bubeck Wardenburg J, Kobayashi SD, et al. (2011) Molecular differentiation of historic phage-type 80/81 and contemporary epidemic *Staphylococcus aureus*. *Proc Natl Acad Sci U S A* 108: 18091–18096.
16. Malachowa N, Kobayashi SD, Braughton KR, Whitney AR, Parnell MJ, et al. (2012) *Staphylococcus aureus* leukotoxin GH promotes inflammation. *J Infect Dis* 206: 1185–1193.
17. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J (2012) ADAM10 mediates vascular injury induced by *Staphylococcus aureus* alpha-hemolysin. *J Infect Dis* 206: 352–356.
18. Alonzo F, 3rd, Benson MA, Chen J, Novick RP, Shopsin B, et al. (2012) *Staphylococcus aureus* leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. *Mol Microbiol* 83: 423–435.
19. Dumont AL, Nygaard TK, Watkins RL, Smith A, Kozhaya L, et al. (2011) Characterization of a new cytotoxin that contributes to *Staphylococcus aureus* pathogenesis. *Mol Microbiol* 79: 814–825.
20. Nizet V (2007) Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. *J Allergy Clin Immunol* 120: 13–22.
21. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, et al. (2004) Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial antiinflammatory agent. *J Exp Med* 199: 687–695.
22. Postma B, Poppelier MJ, van Galen JC, Prossnitz ER, van Strijp JA, et al. (2004) Chemotaxis inhibitory protein of *Staphylococcus aureus* binds specifically to the C5a and formylated peptide receptor. *J Immunol* 172: 6994–7001.
23. Rooijackers SH, Ruyken M, Roos A, Daha MR, Presanis JS, et al. (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. *Nat Immunol* 6: 920–927.
24. Rooijackers SH, Ruyken M, van Roon J, van Kessel KP, van Strijp JA, et al. (2006) Early expression of SCIN and CHIPS drives instant immune evasion by *Staphylococcus aureus*. *Cell Microbiol* 8: 1282–1293.
25. Lindmark R, Thoren-Tolling K, Sjoquist J (1983) Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. *J Immunol Methods* 62: 1–13.
26. Goodyear CS, Silverman GJ (2004) Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. *Proc Natl Acad Sci U S A* 101: 11392–11397.
27. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, et al. (2009) Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. *Faseb J* 23: 3393–3404.
28. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O (2010) Nontoxicogenic protein A vaccine for methicillin-resistant *Staphylococcus aureus* infections in mice. *J Exp Med* 207: 1863–1870.
29. Palmqvist N, Foster T, Tarkowski A, Josefsson E (2002) Protein A is a virulence factor in *Staphylococcus aureus* arthritis and septic death. *Microb Pathog* 33: 239–249.
30. Reyes-Robles T, Alonzo F, 3rd, Kozhaya L, Lacy DB, Unutmaz D, et al. (2013) *Staphylococcus aureus* Leukotoxin ED Targets the Chemokine Receptors CXCR1 and CXCR2 to Kill Leukocytes and Promote Infection. *Cell Host Microbe* 14: 453–459.
31. Panizzi P, Friedrich R, Fuentes-Prior P, Richter K, Bock PE, et al. (2006) Fibrinogen substrate recognition by staphylocoagulase (pro)thrombin complexes. *J Biol Chem* 281: 1179–1187.
32. Bjerketorp J, Jacobsson K, Frykberg L (2004) The von Willebrand factor-binding protein (vWbp) of *Staphylococcus aureus* is a coagulase. *FEMS Microbiol Lett* 234: 309–314.
33. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, et al. (2011) Preventing *Staphylococcus aureus* sepsis through the inhibition of its agglutination in blood. *PLoS Pathog* 7: e1002307. doi:10.1371/journal.ppat.1002307
34. Schouten M, Wiersinga WJ, Levi M, van der Poll T (2008) Inflammation, endothelium, and coagulation in sepsis. *J Leukoc Biol* 83: 536–545.
35. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. *Nat Rev Immunol* 13: 34–45.
36. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P (2013) Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. *Nat Immunol* 14: 785–792.
37. Bhakdi S, Muhly M, Mannhardt U, Hugo F, Klapettek K, et al. (1988) Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets. *J Exp Med* 168: 527–542.
38. Edwards AM, Potts JR, Josefsson E, Massey RC (2010) *Staphylococcus aureus* host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA. *PLoS Pathog* 6: e1000964. doi:10.1371/journal.ppat.1000964
39. Carnes EC, Lopez DM, Donegan NP, Cheung A, Gresham H, et al. (2010) Confinement-induced quorum sensing of individual *Staphylococcus aureus* bacteria. *Nat Chem Biol* 6: 41–45.
40. Bagnoli F, Bertholet S, Grandi G (2012) Inferring reasons for the failure of *Staphylococcus aureus* vaccines in clinical trials. *Front Cell Infect Microbiol* 2: 16.
41. Lemichez E, Lecuit M, Nassif X, Bourdoulous S (2010) Breaking the wall: targeting of the endothelium by pathogenic bacteria. *Nat Rev Microbiol* 8: 93–104.